富煌鋼構(002743.SZ):與萬華化學旗下萬華物資簽訂11.68億元的採購合同
格隆匯5月11日丨富煌鋼構(002743.SZ)公佈,公司近日與萬華化學集團股份有限公司全資子公司萬華化學集團物資有限公司(“萬華物資”)分別簽訂了《採購框架合同(一)》和《採購框架合同(二)》,約定由公司分別承接煙台(含蓬萊地區)成品鋼結構框架及寧波成品鋼結構框架,項目合同暫定含税價款分別為1,043,021,840元和125,048,692元。
此次公司和萬華物資簽訂的上述合同總額暫定含税價款116,807.05萬元,約佔公司最近一個經審計會計年度(2022年)營業收入的24.55%。若該項目能夠順利推進實施,預計將對公司未來經營業績產生較為積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.